RSS   Newsletter   Contact   Advertise with us

Vaxxel acquires Transgene's DuckCelt-T17 cell line to develop vaccines

Christian Fernsby ▼ | May 4, 2020
Vaxxel SAS, a French start-up, developing vaccines against respiratory viral infections, announces the acquisition of Transgene’s proprietary DuckCelt®-T17 cell line.
French   Vaxxel
The terms of the agreement are confidential.

Topics: Vaxxel Transgene

Through this agreement, Transgene becomes a shareholder of Vaxxel.

DuckCelt-T17, initially developed and patented by Transgene, is an avian cell line grown in suspension.

It is permissive to a variety of viruses, including Influenza viruses and human Metapneumoviruses.

The cell line has a demonstrated capability to be used at industrial scale.